At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
EVFM Evofem Biosciences, Inc.
Post-Mkt 02-02 16:00:04 EST Delay
盘后0.0090
+0.0002+2.27%
16:00 EST
Evofem CEO Demands Overhaul of Women’s Health at Fierce JPM Week 2026
Reuters  ·  01-26
Evofem CEO Demands Overhaul of Women’s Health at Fierce JPM Week 2026
Evofem Biosciences Inc. held annual shareholder meeting
Reuters  ·  2025-11-27
Evofem Biosciences Inc. held annual shareholder meeting
Evofem Biosciences Q3 net sales rise
Reuters  ·  2025-11-14
Evofem Biosciences Q3 net sales rise
Evofem Biosciences Q3 Pretax Profit USD -1.573 Million
THOMSON REUTERS  ·  2025-11-14
Evofem Biosciences Q3 Pretax Profit USD -1.573 Million
Evofem Biosciences Inc. Announces Date for Upcoming Annual Meeting of Stockholders
Reuters  ·  2025-10-21
Evofem Biosciences Inc. Announces Date for Upcoming Annual Meeting of Stockholders
Evofem Biosciences Inc: Delivered Notice of Termination to Aditxt Notifying That Co Was Exercising Its Right to Terminate Merger Agreement
THOMSON REUTERS  ·  2025-10-21
Evofem Biosciences Inc: Delivered Notice of Termination to Aditxt Notifying That Co Was Exercising Its Right to Terminate Merger Agreement
Press Release: Evofem Announces Voting Results from Special Meeting of Stockholders
Dow Jones  ·  2025-10-21
Press Release: Evofem Announces Voting Results from Special Meeting of Stockholders
Evofem Biosciences Amends Debt Terms with Adjuvant Funds
Reuters  ·  2025-10-18
Evofem Biosciences Amends Debt Terms with Adjuvant Funds
Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis
Reuters  ·  2025-10-01
Evofem Biosciences’ SOLOSEC® Under Regulatory Review in UAE for Treatment of Bacterial Vaginosis and Trichomoniasis
BRIEF-Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting
Reuters  ·  2025-09-09
BRIEF-Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting
Evofem Anticipates Approval of Merger With Aditxt at Upcoming Stockholder Meeting
THOMSON REUTERS  ·  2025-09-09
Evofem Anticipates Approval of Merger With Aditxt at Upcoming Stockholder Meeting
ADiTx Inc. Updates Merger Agreement with Evofem, Adjusts Equity Investment Dates and Amounts
Reuters  ·  2025-08-28
ADiTx Inc. Updates Merger Agreement with Evofem, Adjusts Equity Investment Dates and Amounts
Evofem Biosciences Secures New Patent for SOLOSEC, Extending Market Exclusivity into 2041
Reuters  ·  2025-08-19
Evofem Biosciences Secures New Patent for SOLOSEC, Extending Market Exclusivity into 2041
Evofem Biosciences Inc. Reports 16% Increase in Q2 2025 Net Sales; Net Loss of $1.8M and EPS of $(0.02)
Reuters  ·  2025-08-14
Evofem Biosciences Inc. Reports 16% Increase in Q2 2025 Net Sales; Net Loss of $1.8M and EPS of $(0.02)
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
THOMSON REUTERS  ·  2025-08-14
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update
Evofem Biosciences Q2 Pretax Profit USD -1.777 Million
THOMSON REUTERS  ·  2025-08-14
Evofem Biosciences Q2 Pretax Profit USD -1.777 Million
ADiTx Inc. Announces Board Changes: Jeffrey Runge and Saundra Pelletier to Step Down, Pelletier to Join Adifem Post-Merger
Reuters  ·  2025-08-09
ADiTx Inc. Announces Board Changes: Jeffrey Runge and Saundra Pelletier to Step Down, Pelletier to Join Adifem Post-Merger
Evofem Biosciences Inc. Increases Authorized Shares to 10,000 for Preferred Stock Dividends
Reuters  ·  2025-08-06
Evofem Biosciences Inc. Increases Authorized Shares to 10,000 for Preferred Stock Dividends

Introduction

Company Name.
Evofem Biosciences, Inc.
Affiliated Markets:
PINK
Listing Date:
--
Main Business:
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Issue price:
--